0
GUSTO trial focuses on muscle-invasive bladder cancer treatment.
Aims to tailor therapy based on genetic subtypes.
Achieves rapid gene expression results in under 7 days.
Team includes multiple healthcare professionals and partners.
Received recognition from the Royal College of Pathologists.
Potential to inform design of phase 3 trials.
Demonstrates importance of academic-clinical partnerships in diagnostics.
